Gilead Sciences, Inc. $GILD Shares Sold by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 482,201 shares of the biopharmaceutical company’s stock after selling 70,572 shares during the period. TD Waterhouse Canada Inc.’s holdings in Gilead Sciences were worth $60,789,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the business. Aviva PLC raised its position in Gilead Sciences by 5.4% during the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after acquiring an additional 59,782 shares during the period. Life Cycle Investment Partners Ltd acquired a new stake in Gilead Sciences during the 4th quarter worth $1,418,000. Bank of Nova Scotia purchased a new stake in shares of Gilead Sciences during the second quarter worth $100,056,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Gilead Sciences during the second quarter worth $55,754,000. Finally, Harvest Fund Management Co. Ltd raised its position in shares of Gilead Sciences by 14.4% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock valued at $13,075,000 after buying an additional 13,385 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the sale, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. The trade was a 33.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the transaction, the insider directly owned 118,234 shares in the company, valued at $16,273,727.76. The trade was a 19.15% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 105,000 shares of company stock worth $14,495,820. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.1%

GILD stock opened at $151.22 on Friday. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29. The firm has a market cap of $187.51 billion, a PE ratio of -56.64 and a beta of 0.33. The firm’s 50 day moving average price is $136.21 and its 200-day moving average price is $136.42. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.01 earnings per share. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is currently -122.85%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts raised Gilead’s earnings forecasts and upgraded the stock to “Strong Buy.” Zacks increased its 2027 quarterly EPS estimates and lifted its full-year forecast to $9.36 from $9.30. It also raised its FY2028 estimate to $9.66 from $9.58, suggesting expectations for improving profitability. Zacks upgrade and earnings estimates
• Positive Sentiment: Gilead’s latest results provided a favorable foundation for the rally. The company reported quarterly revenue of $7.80 billion, above the $7.40 billion consensus estimate, while its loss per share was narrower than expected. Revenue increased 10.6% year over year, giving investors confidence in the business despite currently negative reported earnings. Gilead post-earnings performance
• Positive Sentiment: A partner-backed stomach-cancer trial reached completion, creating a potential immuno-oncology catalyst. The milestone involving Arcus-supported research could provide important future data for Gilead’s oncology strategy, although the eventual investment impact depends on trial results and regulatory progress. Gilead cancer trial milestone
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The sale reduced his ownership by 2.53%, but it was conducted under a pre-arranged Rule 10b5-1 trading plan, making it a limited bearish signal. SEC insider trading filing

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Rothschild & Co Redburn lowered their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $158.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.